SRZNW NASDAQ

Surrozen, Inc. is a biotechnology company dedicated to identifying and advancing therapeutic candidates. Their core strategy involves precisely influencing the Wnt signaling pathway to promote the body's natural processes of tissue restoration and regeneration. To achieve this, Surrozen engineers antibodies that target specific tissues, aiming to activate the intrinsic repair systems of the body. These innovative therapies hold promise for a wide range of medical conditions affecting organs such as the intestine, liver, eyes (retina, cornea), lungs, kidneys, inner ear (cochlea), skin, pancreas, and the central nervous system. Among its pipeline assets, SZN-043 is designed to foster the regeneration of liver cells (hepatocytes), thereby enhancing liver function and mitigating fibrosis. Additionally, SZN-1326 is a novel bi-specific human antibody. This agent specifically interacts with Frizzled and LRP receptors, which are abundantly found in intestinal crypts, to directly regulate Wnt signaling within the target intestinal tissue. Established in 2016, Surrozen, Inc. operates from its headquarters in South San Francisco, California.